Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study by Thursz, Mark et al.
1 
 
Alcohol-related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for 
Further Study 
 
Gyongyi Szabo gyongyi.szabo@umassmed.edu*1#, Patrick S. Kamath 
kamath.patrick@mayo.edu2*, Vijay H. Shah shah.vijay@mayo.edu*3, Mark Thursz 
m.thursz@imperial.ac.uk*4, Philippe Mathurin philippe.mathurin@chru-lille.fr*5 
 
*All authors contributed equally to the work in this manuscript 
#Corresponding Author 
 
1University of Massachusetts Medical School, Department of Medicine, 364 Plantation Street, 
LRB-208, Worcester, MA, USA 01605-2324 
2Mayo Clinic, Division of GI and Internal Medicine, 200 First Street SW, Rochester, MN, USA 
55905 
3Mayo Clinic, Gastroenterology and Hepatology, 200 First Street, SW, Rochester, MN, USA 
55905 
4Imperial College of School of Medicine at St. Mary's, Department of Medicine, Norfolk Place, 
London, UK W21NY, 0207-594-3851 
5Hôpital Huriez, Service des maladies de l’appareil digestif, Rue Polonovski, Lille, FR F-59037 
Lille  
 
See Appendix for the full list of all speakers from the Conference. 
 
This report summarizes the highlights of the first AASLD-EASL Joint Conference on Alcohol-
related Liver Disease and Alcoholic Hepatitis.  
 
Keywords: Alcoholic Liver Disease; Alcoholic Hepatitis 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Corresponding Author:  Gyongyi Szabo 
University of Massachusetts Medical School  
Department of Medicine, LRB 208 
364 Plantation Street 
Worcester, MA, USA 01605-2324 
508-856-5275 
Gyongyi.Szabo@umassmed.edu 
 
 
Abbreviations: European Association for the Study of the Liver (EASL); American Association 
for the Study of Liver Disease (AASLD); nonalcoholic fatty liver disease (NAFLD); 
nonalcoholic steatohepatitis (NASH); alcoholic hepatitis (AH); Maddrey Discriminant Function 
(MDF); magnetic resonance (MR); United Network for Organ Sharing (UNOS) 
 
Financial Support: none 
 
  
3 
 
A joint meeting of the European Association for the Study of the Liver (EASL) and the 
American Association for the Study of Liver Disease (AASLD) was held in London on 
September 30 and October 1, 2017.  The goals of the meeting were to identify areas of broad 
agreement and disagreement, develop consensus, and inform future directions to ultimately 
reduce the burden, morbidity, and mortality of alcohol-related liver disease (previously termed 
alcoholic liver disease).  The specific aims of the meeting were to identify unmet needs and areas 
for future investigation to reduce alcohol consumption; develop markers for diagnosis and 
prognosis of disease; and create a framework to test novel pharmacological agents with pre-
specified treatment end-points.  A table summary of these goals and aims is provided in context 
of epidemiology (Table 1), current management strategies (Table 2), next steps for future trials 
(Table 3) and translational science (Table 4).  
 
EPIDEMIOLOGY, ADDICTION, DIAGNOSIS AND DISEASE PROGRESSION 
FACTORS IN ALCOHOL-RELATED LIVER DISEASE  
Epidemiology  
Worldwide, approximately 2.4 billion people consume alcohol with 1·5 billion (1·4–1·6) 
male current drinkers and 0·9 billion (0·8–1·0) female current drinkers (1).  Approximately 2 
million globally die of liver disease each year, and up to 50% of mortality with cirrhosis is 
attributable to alcohol. Alcohol-related liver disease represents one of the top 30 causes of death 
in recent studies of global burden of disease.  In 2010, the worldwide rate of alcohol-attributable 
cirrhosis death was 7.2 deaths per 100,000 people (4.6 in females and 9.7 in males) (2). 
Total per capita consumption of alcohol varies from continent to continent, from country 
to country within a continent, and from region to region within a country. As an example, total 
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per capita annual consumption is at about 10 L/adult in the U.S., 12-13 L in France, 11-12 L in 
the UK, 7-8 L in Italy and 11-13 L in Eastern Europe, whereas it is only 0-2 L in North 
Africa/Middle East (3). 
Regardless of the variation from country to country, liver-related death rates correlate 
with alcohol consumption in a given country.  For example, a decrease in overall alcohol 
consumption in the wine-drinking countries of southern Europe has driven reduction in cirrhosis 
mortality rates whereas a substantial increase has been observed in Britain for both men and 
women (4).  Despite the high global burden of mortality due to alcohol-related liver disease, both 
in terms of number of deaths and in terms of years of life lost, the estimates may actually 
underrepresent the true burden of disease.  Because of this, international comparisons of the 
burden of alcohol-related liver disease are problematic and often unreliable.  Indeed, much of 
this information relies on coding of death certificates.  An example of coding errors includes a 
lack of willingness of many providers to attribute cirrhosis death to alcohol.  This may lead to 
significant under-reporting of alcohol-related liver disease, especially alcohol-related cirrhosis.  
It is also unknown whether the risk of alcohol associated liver disease depends on the type of 
alcohol imbibed, whether alcohol is consumed with foods or on an empty stomach, whether 
certain foods are protective, and whether binge drinking clearly confers a higher risk.  The 
severity of alcohol-related liver disease in all its stages is potentiated by obesity, but genetic risk 
factors for both alcohol misuse and alcohol-related liver disease are unclear.   
 
Public Health Policy relating to alcohol-related liver disease 
Given the link between alcohol consumption and alcohol-related liver disease, it follows 
that public health policy substantially influences mortality rates.  In fact, public policies are more 
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effective than education and approaches at the individual level.  The dominant strategies for 
public intervention include pricing and marketing (5), with price being the single strongest driver 
of alcohol use.  When pricing rises, alcohol consumption and alcohol-related liver disease 
commensurately decrease.  Conversely, when prices drop, alcohol consumption and alcohol-
related death rates increase.  The best approach for pricing strategies focuses on taxation.  
Availability can also be regulated at the government level by determining days and hours of sale 
and state control over outlets of sale.  Simple measures to reduce alcohol consumption have been 
proposed, such as regular incremental above inflation tax increase, a minimal price of alcohol, 
protecting children from alcohol marketing, and clinicians, especially primary care physicians, 
advising all their patients to reduce alcohol consumption (5).  Finally, government can also 
regulate a number of marketing features, including the prevention of targeting selected 
vulnerable populations such as young individuals and banning sports sponsorship.  Despite these 
tools that government possesses to influence alcohol consumption, there are a number of 
counter-regulatory goals and lobbying initiatives that combat the effectiveness of government 
regulations.   
 
Alcohol Use Disorder 
Alcohol use disorders represent a chronic and relapsing disease which affects nearly one 
in ten individuals of the general population in the western world.  Given that continued alcohol 
consumption after the onset of liver disease increases liver-related morbidity and mortality, the 
ideal focus of treatment in these patients is long-term abstinence and prevention of relapse.  
There is strong evidence that the most effective strategy to reduce alcohol intake, promote 
abstinence, and prevent relapse at the individual level is the combination of psychosocial and 
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pharmacologic intervention (6).  One of the few randomized controlled trials comparing modes 
of psychosocial therapy in patients specifically with alcohol related liver disease supported the 
use of motivational enhancement therapy although other counseling approaches are also widely 
utilized (7, 8).  A number of medications have been approved for treatment of alcohol-use 
disorders including disulfiram, naltrexone, nalmefene, and acamprosate (9).  Additional drugs 
are also under intense investigation, including topiramate, ondansetron, and baclofen (10).  
However, a major limitation is that most of these drugs have not been tested in patients with 
alcohol use disorder who also have advanced liver disease.  The medication with the strongest 
evidence for effectiveness and safety in this group of patients is baclofen given that this is the 
only anti-craving medication formally tested in randomized controlled trials in patients with 
alcohol use disorder and cirrhosis (11).  Baclofen is approved in some countries but is not FDA 
approved in the U.S. for this use.  Thus, a major unmet need is further validation of a 
pharmacologic intervention for patients with alcohol use disorders with cirrhosis.  Further 
complicating this issue is the lack of proper care models in many parts of the world (e.g., patients 
with alcohol use disorder and cirrhosis fall in the gap between addiction specialists and 
hepatologists).  Another unmet need is a reliable and discrete remote monitoring and/or digital 
health solutions for ascertaining alcohol consumption.  Nonetheless, screening for alcohol related 
liver disease in high risk populations is recommended at the primary care level.  Based on recent 
evidence screening strategies have been proposed for alcohol related liver disease in at-risk 
populations although validation is required (12). 
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Co-factors and Genetics 
Progression and prognosis of alcohol-related liver disease is influenced by important co-
factors, most notably, fatty liver disease due to metabolic syndrome and viral hepatitis.  Indeed, 
there has been a progressive rise in the prevalence of obesity and of Type II diabetes in the 
general population and alcohol-related liver disease is frequently superimposed on obesity.  
Recent population-based studies have found that obese individuals who consume alcohol may 
have a greater likelihood of having hepatic steatosis and alcohol consumption increases the risk 
of fatty liver in individuals with obesity.  Furthermore, obesity may negatively impact alcohol-
related liver disease progression and prognosis.  These observations suggest that there are 
additive and/or synergistic interactions of variables associated with nonalcoholic fatty liver 
disease (NAFLD) in combination with variables associated with alcohol-related liver disease, 
most notably the amount of alcohol consumption.  This has led to recommendations to curtail 
alcohol use in individuals with nonalcoholic steatohepatitis (NASH) and conversely to manage 
weight and risk factors for NASH in individuals with alcohol-related liver disease.  Though 
small studies have suggested there may be potential beneficial effects of low levels of alcohol 
consumption in individuals with NASH, the majority of studies showing a benefit of low levels 
of alcohol consumption are focused in healthy individuals.  In a recent study, alcohol use 
≥210 g/week for men and ≥ 140 g/week for women was associated with a higher risk of severe 
complications of liver disease in the general population (13).  The interaction between alcohol 
consumption and obesity is clearly an area that needs further investigation.  Another co-variable 
is non-hepatic co-morbidity that is increasing in patients with alcohol-related liver disease (14).  
Indeed, a recent analysis of electronic medical records demonstrate that the Charlson 
Comorbidity Index has increased substantially over the last decade and that patients in the U.S. 
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presenting with alcoholic hepatitis (AH) are older and more likely to have multiple systemic 
comorbidities such as COPD (14).  This may also adversely affect the prognosis of alcohol-
related liver disease.  However, there are positive co-factors to consider as well.  For example, 
coffee drinking has been shown to be protective in alcohol-related liver disease although this 
requires much more detailed investigation before application can be proposed (15).  There may 
also be microbiome characteristics that afford protection of more severe prognoses in patients 
with alcohol-related liver disease.  
There is now increasing evidence that supports a genetic basis for alcohol-related liver 
disease.  Since all individuals who drink in excess do not develop liver disease there is clearly a 
genetic risk in alcohol-related liver disease.  The genetic loci that have been best studied and 
validated include PNPLA33, TM6SF2, and MBOAT7 (16, 17).  It is important to note that these 
genetic profiles are distinct from other genetic loci, which may predispose towards alcohol 
misuse as aforementioned loci focus on liver injury in response to alcohol consumption.  The 
allelic risk conferred by these genetic variants approximates about 2.5-fold which is surprisingly 
high for a genetically-complex disorder such as alcohol-related liver disease and may be related 
to biases related to the choice of the control groups (16).  Interestingly, all three of these 
mutations are also risk factors for NAFLD/NASH and all three genes are “lipid genes” (18).  For 
example, PNPLA3 is a triglyceride lipase, while TM6SF2 plays a role in VLDL lipidation, and 
MBOAT7 is a lysophosphatidylinositol acyltransferase (18).  It may be that PNPLA3 is most 
relevant for steatosis and hepatocellular cancer in alcohol-related liver disease, while TM6SF2 is 
relevant for inflammation and fibrosis progression in hepatocellular cancer, and MBOAT7 is 
most notable for fibrosis progression (16).  However, this hypothesis needs further validation.  
Most recently, a splice variant encoding a lipid droplet protein was associated with a reduced risk 
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of progression from steatosis to hepatitis (19).  Future studies will hopefully allow us to 
“individualize” care for patients with alcohol-related liver disease based on genetic 
predispositions, especially if “druggable” targets can be developed for the phenotypic alterations 
associated with the genetic profiles.   
 
Alcohol-related Liver Disease  
Alcohol-related liver disease covers a spectrum including fatty liver disease, alcoholic 
hepatitis, and cirrhosis and its complications.  The type and severity of steatosis and extent of 
fibrosis are independent predictive factors of fibrosis progression and the highest risk of disease 
progression is observed in heavy drinkers with alcoholic hepatitis (20-23).  Approximately 3% of 
patients with alcoholic hepatitis progress to cirrhosis annually.  Epidemiological data show a 
strong correlation between severity and duration of alcohol abuse and the presence of cirrhosis.  
Among a cohort of 6970 adult subjects from a general population, the rate of cirrhosis was 
significantly higher in patients who consumed ≥ 30 g / d than among abstinent controls or those 
with consumption <30 g / day (2.2% vs 0.08%).  Subjects with alcohol consumption > 120 g 
/day had the highest risk of cirrhosis (around 13.5% (24)). 
Epidemiological data focusing on alcoholic hepatitis are sparse.  In Denmark, from 1999 
through 2008, the incidence of alcoholic hepatitis increased from 37 to 46 per million for men 
and from 24 to 34 per million for women.  The increase in alcoholic hepatitis paralleled the 
increase in alcohol consumption (25).  In the U.S., alcoholic hepatitis-related hospitalization 
increased from 249,884 in 2002 to 326,403 in 2010 (26).  Cost of each hospitalization increased 
by 40.7% in 2010 compared to 2002 after adjustment on inflation over this period (26).  Outside 
of these studies, information on burden of alcoholic hepatitis is missing and future 
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epidemiological studies should focus on evolution of the burden of alcoholic hepatitis, including 
less severe disease.   
The most dramatic presentation of alcohol-related liver disease is alcoholic hepatitis 
which manifests as rapid onset of jaundice and, in severe forms, may lead to acute-on-chronic 
liver failure with hepatic and extrahepatic organ failure, and mortality around 30% at one month.  
However, a symptomatic form of disease is also recognized where patients may be entirely 
asymptomatic but laboratory tests and liver biopsy show changes of steatohepatitis.   
The currently accepted definition of alcoholic hepatitis is rapid onset of jaundice 
(bilirubin > 3 mg/dL) with AST (>50 IU/mL), and AST to ALT ratio of > 1.5 in patients with 
heavy alcohol use (27).  Heavy alcohol use is generally defined as more than 3 standard drinks 
per day for women (approximately 40 grams of alcohol), and four standard drinks per day for 
men (approximately 50-60 grams of alcohol).  It is important to emphasize that standard drinks 
differ between countries.  Liver biopsy remains the standard for making a diagnosis of alcoholic 
hepatitis though patients may be entered into clinical protocols with a clinical diagnosis, which is 
defined as heavy alcohol use with typical liver biochemistry and exclusion of other causes of 
liver disease.  However, relying on clinical criteria alone may be associated with a risk of 
wrongly classifying patients with or without alcoholic hepatitis; on the other hand, there is also 
inter observer variation in assessment of severity of alcoholic hepatitis on liver biopsy. 
 In order to decrease the risk of misclassification for future studies evaluating drugs, the 
NIAAA consortium has proposed 3 groups (27): a) the most definitive diagnosis requires both 
clinical and histological documentation and has been referred to as definite alcoholic hepatitis 
(27); b) in the absence of histologic confirmation but typical liver biochemistry and exclusion of 
confounding variables, the diagnosis is referred to as probable alcoholic hepatitis (27); and c) in 
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the absence of histology and in the presence of potential confounding variables, the diagnosis is 
possible alcoholic hepatitis (27).  
Alcoholic hepatitis may be stratified as mild, moderate, and severe.  Severe alcoholic 
hepatitis has traditionally been defined by a Maddrey Discriminant Function (MDF) score of ≥32 
that predicts mortality of up to 30% at 30 days (28-30).  Other scorings such as the MELD score, 
ABIC score (28-30), and the Glasgow score (31) have also been used and may be superior to the 
MDF score (32).  It is unclear whether change in any of these scores can be used as a surrogate 
end-point for survival, especially with less severe AH.  Since patients with an MDF ≤ 32 still 
have a significant risk for mortality, it has been proposed that the MELD score be used to stratify 
severity of alcoholic hepatitis.  A MELD score ≥20 is used to define severe alcoholic hepatitis 
which is associated with mortality being approximately 20%-40% at 90 days (33, 34).  MELD 
score of 11 to 20 defines a group with moderately-severe alcoholic hepatitis; and MELD score ≤ 
10 defines mild hepatitis.  The natural history of the mild and moderately severe groups is 
unclear.  It is also not known whether patients with moderately severe AH who do have a 
mortality risk have survival benefit from abstinence alone or if pharmacological therapy is 
required in addition. 
The Lille score is used to determine response to steroid therapy at one week (35).  
Corticosteroids can be stopped at day 7 in non-responders (i.e., those with a Lille score ≥0.56) as 
these patients do not benefit from continued treatment (36).  It is unknown whether the Lille 
score is a valid marker of treatment outcome for therapies other than corticosteroids. A 
combination of MELD score at baseline and Lille score at 7 days may be used to assess mortality 
at two months and six months and seems to be more accurate, compared with either model alone 
(37).   
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Invasive and Noninvasive Diagnosis of Alcohol-related Liver Disease 
Biopsy is required to make a definitive diagnosis of AH (38-41), but use of liver biopsy 
as a standard of care for diagnosis varies throughout the world.  Histology is also helpful for 
short-term prognosis of alcoholic hepatitis (41) and alcohol-related acute-on-chronic liver failure 
(42).  For example, morphological evidence of bile accumulation (i.e., bilirubinostasis) is 
associated with the development of septic complications.  Importantly, the degree of fibrosis is 
the main predictor of outcome in patients with compensated ALD (40).  The characteristic 
histological findings of severe alcoholic hepatitis include macrovesicular steatosis, parenchymal 
inflammation with mononuclear cells and neutrophils, hepatocellular injury in the form of 
ballooning with abundant Mallory-Denk bodies, necrosis, and canalicular and/or ductular 
cholestasis.  Hepatocellular ballooning is associated with deposition of collagen fibers resulting 
in pericellular and peri-sinusoidal fibrosis (43, 44).  A majority of patients with symptomatic 
alcoholic hepatitis have underlying cirrhosis.  When cirrhosis is established, histological features 
of alcoholic hepatitis and even pericellular fibrosis may not be prominent.  While there is no 
“NAS score” equivalent for histology of alcoholic hepatitis as has been described for NASH, the 
histologic features are interchangeable in the two conditions in most cases.  However, there is 
usually a greater disease severity with severe ballooning, necroinflammation and neutrophils 
surrounding hepatocytes (satellitosis) and bilirubinostasis in patients with alcoholic hepatitis as 
opposed to NASH (41).  This may simply reflect the sicker nature of patients who undergo liver 
biopsy for alcoholic hepatitis as opposed to NASH.  In addition, fibro-obliterative venous lesions 
and sclerosing hyaline necrosis are typical for alcohol associated liver injury and have not been 
described in NAFLD/NASH to date (43). 
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Given the risks, cost, and inconvenience of invasive liver biopsy there is a large focus on 
non-invasive efforts to diagnose and determine prognosis in patients with alcohol-related liver 
disease.  Non-invasive methods rely on two different but complementary approaches: serum 
biomarkers and the measurement of liver stiffness, using elastography modalities, either 
ultrasound- or magnetic resonance (MR)-based (45).  Among ultrasound-based approaches, 
transient elastography, a relatively inexpensive and widely used point-of-care test, is the most 
validated for detection of advanced fibrosis, better at ruling out than ruling in the diagnosis of 
cirrhosis (46).  However, there is no consensus on cut-offs for cirrhosis in the literature and there 
is a risk of false positive results in non-abstinent patients.  Serum biomarkers have been also 
validated (47), but do not increase diagnostic performance when combined with transient 
elastography (47, 48).  MR-based elastography is expensive, less available, and time consuming, 
but possibly more accurate for steatosis and fibrosis assessment (49).  In general, unlike in 
patients with other etiologies of liver disease such as viral hepatitis, non-invasive methods are 
much less well validated in patients with alcohol-related liver diseases, especially in at-risk 
populations (12). 
 
Current Management and Treatment of Alcoholic Hepatitis  
Management of patients should be standardized in clinical trials for optimal assessment 
of the impact of novel agents.  Lack of standardization may result in differences in outcome in 
clinical trials unrelated to the investigational agent.  It has been difficult to stipulate that a liver 
biopsy be performed to confirm the diagnosis of alcoholic hepatitis prior to starting therapy.  
Biopsy could also potentially allow study of molecular pathways of hepatic injury that may 
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inform future novel therapies.  In the absence of liver biopsy, patients with “probable” alcoholic 
hepatitis may be treated as AH similar to those patients with biopsy-confirmed AH. 
There is broad agreement that management of severe alcoholic hepatitis requires 
treatment of the alcohol use disorder and risk for alcohol withdrawal, and treatment of the liver 
disease.  Management of the liver disease in turn requires reversal of the alcoholic hepatitis and 
treatment of complications of alcohol-related cirrhosis including ascites, spontaneous bacterial 
peritonitis, hepatic encephalopathy, and variceal bleeding.   
Treatment of alcoholic hepatitis includes nutritional supplementation to provide adequate 
protein and calories.  Enteral supplementation is the preferred route because of safety and lower 
risk of infections.  Patients require transfer to the Intensive Care Unit only if organ support is 
required.  The role of routine antibiotic therapy is unclear and awaits the results of ongoing 
clinical trials.  Since sepsis is difficult to diagnose in patients with AH, if sepsis is strongly 
suspected, and certainly when infection is diagnosed, broad-spectrum antibiotics should be 
initiated within 1 hour.  The only pharmacological agent recommended for treatment of severe 
alcoholic hepatitis in the absence of contraindications is corticosteroids, namely prednisolone 40 
mg daily or methylprednisolone, 32 mg daily for 28 days.  Pentoxifylline is not recommended as 
therapy for severe AH. 
Corticosteroids are associated with 1-month survival benefit in only about 60% of treated 
patients with severe alcoholic hepatitis and the benefit is not sustained intermediate or longer-
term.  Therefore, physicians may consider early liver transplantation in highly-selected patients 
with alcoholic hepatitis (50-52).  The United Network for Organ Sharing (UNOS) (53), ACG 
Clinical Guideline (54) and the EASL clinical practice guidelines on ALD (45) suggest that 
listing a patient for transplantation should not be based only on the 6-month abstinence rule.  
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When liver transplantation has been carried out in these highly-selected patients, survival has 
been excellent (50-52, 55).  In terms of public opinion, a vast majority of the population of 
donors was not against early liver transplantation for alcoholic hepatitis (56).  Early liver 
transplantation should be considered in the context of ethical principles recommending active 
treatment of patients, without discrimination, and according to best scientific knowledge (57).  
However, due to organ shortage and the stringency of the selection process limiting transplant 
availability, novel pharmacological agents to decrease mortality and progression of disease need 
to be developed for the majority of non-responders to medical therapy.  Living-donor 
transplantation has been carried out in parts of the world where deceased-donor liver 
transplantation is unavailable.  Such an approach requires discussion of the ethics of subjecting a 
donor to risk for an indication of liver transplantation that is still under investigation (57).   
 
Next Steps for Future Trials  
There are a number of reasons for the paucity of clinical trials in alcohol-associated liver 
disease.  Recruitment to clinical trials in this group of patients can be challenging whilst 
endpoints such as mortality require large numbers of subjects to achieve meaningful levels of 
statistical power.  Abstinence or recidivism inevitably affect patient outcomes but cannot be 
predicted.  Nonetheless, clinical trials in early alcohol-related liver disease are very much needed 
to avoid the usual late presentation with decompensated liver disease.  In order to achieve this 
end, patients could be selected in alcohol rehabilitation clinics.  There is also evidence that 
universal screening for alcohol misuse in acute medical admissions is feasible and identifies 
patients at high risk of liver disease (58).  Inclusion criteria should be defined and end-points 
may include prevention of liver-related mortality and complications of liver disease. 
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Patients with alcoholic hepatitis are highly susceptible to infection and systemic 
inflammatory response syndrome which may be exacerbated by immunomodulatory drugs used 
to control hepatic inflammation.  Finally, there is a lack of consensus around the design of 
clinical trials, particularly for the early phases of therapeutic development. 
In alcoholic hepatitis there is a higher level of consensus around the type of patients who 
should be recruited into trials defined by inclusion and exclusion criteria.  Patients with severe 
alcoholic hepatitis, defined by an MDF ≥32, MELD ≥20 or Glasgow alcoholic hepatitis score ≥9, 
are considered a priority for therapeutic drug trials but it is now acknowledged that patients with 
milder disease states may also benefit from treatment given that the mortality in this group at 90 
days may be as high as 15-20%.  Patients who have recently suffered a significant 
gastrointestinal hemorrhage where hemodynamic instability may have caused hepatic ischemia 
should be excluded.  Similarly, patients with significant renal impairment (serum creatinine > 3 
mg/dl) at the time of randomization should be excluded as acute kidney injury is established as a 
poor prognostic factor.  The need for ventilator or vasopressor support is also an exclusion 
criteria.  Patients with viral hepatitis and active viral replication (HBsAg positive or HCV RNA 
positive) may be excluded as candidate immunomodulatory drugs might adversely affect the 
course of the viral infection.  Active infection at the time of evaluation should not be considered 
an exclusion criterion, assuming the infection is controlled prior to randomization, as treated 
infection has been shown not to adversely influence mortality rates.  
Recent progress in knowledge of the outcome of patients with AH allows experts to 
propose a more evidence-based approach that will help health agencies validate endpoints 
adapted to the specific stages of disease.  Short-term outcome is mainly driven by severity of 
liver injury at baseline and early improvement in hepatic function whereas the most important 
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determinant of outcome longer-term is abstinence (59).  As a consequence, study designs testing 
therapeutic strategies that target the acute insult should focus on liver-related end-points for the 
short term.  Three months seems to be the optimal end-point as 80% of the deaths at short-term 
occur within 3 months and relapse in alcoholism starting around 2-3 months does not 
significantly affect mortality at 3 months but is a contributing factor to long-term mortality.  As a 
consequence, there is clear consensus that the primary outcome in phase III trials for patients 
with severe alcoholic hepatitis should be a mortality rate at 90 days.  Future study designs may 
propose a 3-month duration of drug exposure in order to maintain improvement in liver injury 
over this period and avoid the potential bias of analysis of outcome at 3 months far removed 
from short treatment durations.  It is also clear that pharmacological interventions may incur 
adverse events affecting mortality at earlier time points.  Criteria need to be developed to 
ascertain DILI and drug-induced kidney injury in this population of patients who may have 
worsening of liver and kidney function as a result of the underlying disease alone.  The number 
of patients required to show mortality benefit with a reasonable study power is high and new 
primary outcomes are required for phase II trials.  Unfortunately, there is no consensus on the 
ideal surrogate primary endpoint.  Changes in bilirubin levels at day 7 or the Lille score may be 
good indicators for some investigational agents but are unlikely to be appropriate for drugs with 
slower onset of activity or late side effects.  
Only drugs that target either the key pathways involved in liver injury or the main 
mechanisms of early deaths demonstrated in clinical studies, translational research and animal 
models should be tested.  Endpoints for phase I and II studies will be different from those 
proposed for phase III studies.  An agreement of experts and health agencies is urgently required 
on the different primary end points for phase I, II and III studies, so that pharmaceutical 
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companies and scientific societies can plan development of future clinical trials.  Characteristics 
of patients included in phase I-II trials will also differ from those in phase III trials.  The optimal 
candidates for phase I-II studies should be patients with low risk of mortality to ensure sufficient 
exposure to study drugs.  Up to now, short-term mortality has been the only validated primary 
end point for testing drug efficacy in phase III studies.  However, there is an urgent need to 
validate surrogate markers strongly associated with short-term mortality that may be used in the 
future as primary endpoints for phase III studies. 
Unfortunately, there is no strong consensus on the treatment of patients randomized to the 
control arm of future studies.  Survival at 28 days is improved by prednisolone but the drug has 
no beneficial effect beyond this point.  Therefore, it makes sense to use prednisolone in the 
control arm in studies where the endpoint is 28-day survival and placebo when longer endpoints 
are being considered.  Heterogeneity in the risk of adverse outcomes is widely recognized in 
patients with alcoholic hepatitis and stratification at the time of randomization might be usefully 
deployed in trials to minimize differences between active and control arms.  Consensus is 
evolving towards using the MELD score for mortality stratification.  Other potential stratification 
factors include treatment centers and risk of infection which might be estimated based on 
bacterial 16S ribosomal DNA levels in whole blood samples.  
A consistent reporting system should include the incidence of physician initiated courses 
of antibiotics (or antifungal agents), incidence of SIRS and the incidence of infection defined by 
the clinical criteria as recently proposed (60). 
 
Translational science and evolving biomarkers in alcohol-related liver disease  
19 
 
New translational research approaches that cross science from the bench to bedside and 
from bedside to bench are promising.  Basic science and clinical experts agree that translational 
science can aid the diagnosis and management of alcoholic hepatitis by identifying biomarkers 
and/or developing prediction models.  There is a need for biomarkers that predict disease 
outcomes and response to therapy, early detection of infections, identify drug (steroid) 
resistance, or detect alcohol relapse.  
Basic science observations from in vitro studies and from different animal models have 
greatly contributed to the increasing understanding of the pathogenetic mechanism of alcohol 
associated liver disease.  However, there are limitations of the currently used animal models 
because none of them result in the full clinical spectrum of human acute alcoholic hepatitis.  
Animal models can be used to establish proof-of-concept with the caveat that different animal 
models may need to be used for different stages of alcohol-related liver disease.  For example, 
the Lieber DeCarli chronic alcohol diet model results in fatty liver and very mild alcohol-induced 
liver injury (61).  The acute-on-chronic alcohol administration in the NIAAA model shows some 
features of early alcoholic hepatitis including neutrophil infiltration and mild liver fibrosis (62).  
An acute binge in animals with chronic alcohol feeding increases liver damage and neutrophil 
infiltration (63).  The continuous intragastric alcohol feeding model with weekly binge achieves 
most features of alcoholic hepatitis (64-66) including unique activation of the pyroptotic caspase 
4/11-gasdermin-D pathway and its association with liver bacterial load as validated in severe 
alcoholic hepatitis patients but is expensive and requires special surgical expertise to develop 
(66).  The salient features of human acute alcoholic hepatitis such as hyperbilirubinemia and 
fibrosis are not induced significantly in current murine models of alcohol-related liver disease.  
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Combining a high fat diet with continued alcohol administration results in features of human 
alcoholic hepatitis; however, this models the combination of NASH and alcoholic hepatitis (67).  
The evolution of alcohol-related liver disease into cirrhosis does not always include 
distinct episode(s) of alcoholic hepatitis.  Little is known about early alcoholic hepatitis when 
liver inflammation is ongoing, but the patient is asymptomatic.  Since these patients may 
eventually develop severe disease, clinical and translational studies should also focus on low 
grade alcoholic hepatitis to better understand the natural history of disease and impact a larger, 
currently neglected patient population.  
 Biomarker discovery is hampered by the lack of well-defined stages of alcohol-related 
liver disease.  It remains to be determined whether liver biopsy is therefore required in clinical 
studies of biomarker discovery.  Some argue that clinical parameters and/or MELD scores are 
sufficient for identification of biomarkers for disease progression and response to therapy.  
Additional consideration is related to selection of controls and references for biomarkers.  
Biomarker studies will likely need control groups including patients with alcohol use disorder 
without liver disease, patients with liver disease or cirrhosis due to factors other than alcohol, 
and normal healthy controls.  Biomarker discovery and translational research may not only help 
in understanding pathogenesis of disease but may also be incorporated into clinical prediction 
models. 
 There are many candidate biomarkers that have been identified in discovery phases and 
await validation in large well-defined patient populations.  Some of these include circulating 
indicators of gut microbial translocation (endotoxin, bacterial DNA), markers of systemic 
inflammation (cytokines, chemokines), sterile danger molecules (ST2, HMGB1), markers of 
apoptosis and cell death (fragments of keratin 18) and fibrosis markers (68-72)  including 
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cytochrome P4502E1.  In addition to blood-based biomarkers, there are new potential 
biomarkers in exhaled breath and urine.  Finally, the composition of the microbiome in the gut 
and oral cavity may also represent useful sources of biomarkers in ALD. 
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Table 1. Epidemiology, Addiction, Diagnosis, and Disease Progression Factors 
Areas of Consensus 
Public policy: Price availability and marketing are best tactics to manage alcohol consumption at society level. 
Government policies are necessary to regulate marketing promotions via sports sponsorship, use of internet and 
social media, specifically those promotions that target vulnerable populations such as young individuals. 
Increasing consumption of alcohol amongst younger women is recognized as a public health concern as this 
population is at increased risk of development of alcohol-related liver disease. It is essential that this population be 
an important focus of alcohol reduction measures. 
Health policies aiming to reduce per capita consumption should be emphasized to reduce the burden of alcohol 
related liver disease. 
As with diabetes, national health policies should not only consider primary intervention to decrease alcohol use 
but should integrate in their plan secondary or tertiary interventions aiming to prevent development of alcohol 
associated liver disease and its complications in patients with alcohol use disorder. 
Heavy alcohol with obesity leads to adverse consequences. 
Alcohol rehabilitation should begin in hospital for AH patients while addiction trials should activate at time of 
discharge. 
Surveillance for advanced hepatic fibrosis or cirrhosis with non-invasive methods should be promoted in patients 
with excessive alcohol consumption. 
Policies are not uniform regarding early liver transplantation for patients with severe alcoholic hepatitis not 
responding to medical therapy. Societies need to establish guidelines for liver transplantation for alcoholic 
hepatitis based on local legislation framework. 
 
 
 
 
 
 
Unmet Needs and Opportunities for Future Study 
Pharmacologic therapy for AUD/ in patients with alcohol associated liver disease. 
Define parameters for non-invasive imaging of the liver in patients with AUD. 
Define subsets, predictors of outcome in patients with combined AH/NASH. 
Epidemiological studies on the burden of alcoholic hepatitis 
 
Which team member should primarily manage the patient with AUD/ALD.  
Ideal endpoints for AUD/ALD addiction trials.  
Non-invasive staging approach in AUD/ALD patients. 
Best serologic nomogram for determining AH disease severity (MDF, MELD, etc.). 
Role of liver biopsy in AH. 
28 
 
Safe level of alcohol consumption in patients with NASH. 
. 
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Table 2. Current Management and Treatment of Alcoholic Hepatitis 
Areas of Consensus 
Patients with alcoholic hepatitis and MELD<20 or DF<32 have a mortality rate of 10% at 90 days and, 
therefore, cannot be considered as non-severe. It is proposed to use the term “moderate alcoholic hepatitis” 
for patients with alcoholic hepatitis and MELD 11-20; and mild alcoholic hepatitis with MELD ≤10. 
The three-month natural history of moderate alcoholic hepatitis (MELD score 11-20) needs to be defined. It 
is also necessary to define whether pharmacological therapy is required for patients with moderate alcoholic 
hepatitis. 
A team approach with hepatologist, addiction specialist, nutritional expert and social work is desirable for 
treatment of patients with severe AH.   
Liver biopsy is advised prior to treatment for severe alcoholic hepatitis but is not mandatory. 
Inpatient management of severe AH includes: 
 Nutritional Assessment and Optimal Replacement of protein and calories.  
 Transfer to the Intensive Care Unit for organ support.  
 Meticulous investigation for infection.  When infection is diagnosed or strongly suspected, broad 
spectrum antibiotics should be started within one hour. 
 Steroids therapy if there are no contraindications. 
 Lille score should be the preferred tool to access response to steroid therapy.  
 Liver transplantation should be offered to highly selected patients who fail medical management. 
  
Steroid therapy reduces one-month mortality but does not impact medium term mortality. The absence of 
impact on medium term survival emphasizes the need for newer therapies.   
Living donor liver transplantation should be carried out only after approval of local ethics committees and in 
centers with large experience and where deceased donor transplantation is not available.   
 
 
 
 
Unmet Needs and Opportunities for Future Study 
Validation of histological endpoints as a surrogate for a clinical event. 
Non-invasive methods for the diagnosis of alcoholic hepatitis when considering the limitations of liver 
biopsy. 
Studies comparing long-term alcoholism behavior of patients with early transplantation to patients 
undergoing transplantation after abstaining from alcohol for a 6-month period. 
 
Routine use of antibiotics in all patients with severe alcoholic hepatitis.   
Specific contraindications to steroids.  
Criteria for “futility” to exclude patients from studies. 
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Table 3. Next Steps for Future Trials 
Areas of Consensus 
The optimal time frame of survival endpoint for studies testing new molecules in the setting of severe alcoholic 
hepatitis should be 90 days. 
Liver biopsy is recommended for patients entering Phase I-II studies and may be informative for Phase III 
studies. 
Calculation of sample size in future Phase III studies without liver biopsy should integrate the risk of 
misclassification based on NIAAA classification as also inter-observer agreement in liver biopsy interpretation 
Use of NIAAA classification of alcoholic hepatitis is recommended for design of studies without liver biopsy. 
Only patients with probable or definite AH should be candidates in future studies testing new drugs. 
Lille and other scores should be recorded at different time points to determine response to treatments such as 
regenerative therapies. 
There is the need for surrogate endpoints for survival. We propose a combined endpoint of survival and decrease 
in MELD score as an endpoint for efficacy of a treatment. That is, either mortality or patient who is alive but 
without a decrease in MELD score is study drug failure. 
Unmet Needs and Opportunities for Future Study 
Validation of histological endpoints as a surrogate for a clinical event. 
Developing specific stage/fibrosis scoring systems for ALD 
The concordance between the clinic syndrome of alcoholic hepatitis and histological lesion of steatohepatitis 
needs formal definition. 
The impact of sarcopenia and frailty on outcome and selection of treatment should be explored. 
Criteria of drug-induced liver injury (DILI) and drug induced kidney injury adapted to patients with severe 
alcoholic hepatitis should be established. 
Markers of futility for pharmacological therapy are required to exclude patients from clinical trials (example 
MELD score >35 which is associated with 80% risk of 90-day mortality). 
Consensus for endpoints for Phase I and II studies. 
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Table 4. Translational Science and Evolving Biomarkers 
Areas of Consensus 
Translational science can aid the diagnosis and management of alcoholic hepatitis by developing 
biomarkers to: 
• Predict disease outcomes 
• Predict response to therapy 
• Detect infection early 
• Predict steroid resistance 
• Identify drug resistance 
• Detect alcohol use recidivism 
Clinical criteria to be used in the diagnosis of ALD and AH in biomarker studies should be defined by: 
• Biopsy proven ALD or AH 
• Clinical diagnosis 
• MELD score to determine severity of disease 
Recommended control patient groups: 
• Chronic alcoholics without liver disease 
• Age & sex matched healthy controls 
• Patients with cirrhosis 
• Patients with other liver disease 
Large scale studies in large populations should take advantage of “omics” technologies in biomarker 
discovery. 
Genetic markers should be used in evaluation, prognosis and management of AH.  
Animal models should be used to assess potential biomarkers to establish proof-of-concept for human 
studies. 
 
Unmet Needs and Opportunities for Future Study 
Animal models that accurately model human disease are needed where cholestasis, inflammation, and 
fibrosis are present together.: 
• Alcohol associated liver fibrosis (current models for ALD do not exhibit significant fibrosis) 
• Alcoholic hepatitis 
• Alcoholic cirrhosis 
Need for new biomarkers to: 
• Assess ongoing alcohol use in AH patients after hospital discharge 
• Assess inflammation (Cytokines, Chemokines, PAMPs/DAMPs) 
• Differentiate between infection mediated inflammation and sterile inflammation 
• Predict organ failure 
• Assess liver regeneration 
 
 
